社区

New York, NY – March 12, 2026 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the regulatory clearance of its systems in Argentina. This milestone drives the Company's international growth, supporting a broader mission to expand patient access to highly effective, minimally invasive therapies worldwide.

纽约，2026年3月12日 —— 微创微波消融（MWA）技术的市场领导者百德医疗投资控股有限公司（纳斯达克股票代码：BDMD）（以下简称“百德医疗”或“公司”）今日宣布，其微波消融系统已顺利获得阿根廷监管部门的批准。这一重要里程碑将进一步推动公司的国际化发展，助力实现将高效微创治疗方案惠及全球更多患者的宏大愿景。

The Argentine approval strengthens Baird Medical’s growing portfolio of international certifications, which includes the United States FDA, Indonesia, Malaysia, and Vietnam. Building on this progress, the Company is actively seeking formal registration across several major regions. With applications currently under review in Egypt, Sri Lanka, the Philippines, Pakistan, and other key international markets, Baird Medical is steadily advancing its regulatory pipeline to meet rising global demand. This continued expansion ensures that healthcare providers worldwide are equipped with the advanced tools needed to address a wide variety of soft tissue conditions.

此次在阿根廷成功获批，有力巩固了百德医疗日益丰富的国际认证体系。此前，公司已成功获得美国食品药品监督管理局（FDA）以及印度尼西亚、马来西亚和越南的相关认证。乘此发展势头，公司目前正积极在其他几个核心地区寻求正式注册。

随着在埃及、斯里兰卡、菲律宾、巴基斯坦等关键国际市场的申请进入审核阶段，百德医疗正稳步推进其注册审批流程，以更好地满足日益增长的全球市场需求。公司希望通过持续的全球扩张，支持世界各地的医疗服务提供者配备最先进的医疗设备，从而从容应对各类软组织疾病。

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical’s solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company’s minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact: Eric Huang, PR Liaison

Baird Medical Investment Holdings Ltd.

Phone: +1 (888) 508-6228

Email: ir@bairdmed.com